Prognostic factors in patients with glioblastoma multiforme (clinical research)

被引:1
|
作者
Ekici, Mehmet Ali [1 ]
Bulut, Turgay [2 ]
Tucer, Bulent [3 ]
Basarslan, Seyit Kaan [4 ]
Kurtsoy, Ali [3 ]
机构
[1] Sevket Yilmaz Training & Res Hosp, Dept Neurosurg, Bursa, Turkey
[2] Private Kizilay Hosp, Dept Neurosurg, Kayseri, Turkey
[3] Erciyes Univ, Dept Neurosurg, Fac Med, Kayseri, Turkey
[4] Mustafa Kemal Univ, Fac Med, Dept Neurosurg, Antakya, Turkey
关键词
Glioblastoma multiforme; prognosis; postoperative tumor volume; Karnofsky performance score; MALIGNANT GLIOMAS; P53; GENE; SURVIVAL; RESECTION; MANAGEMENT; SURGERY; ASTROCYTOMAS; CHEMOTHERAPY; RADIOTHERAPY; FEATURES;
D O I
10.3906/sag-1204-45
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To define the independent variables that affect the life spans of patients with glioblastoma multiforme (GBM). Materials and methods: This study was conducted in the neurosurgery clinic of Erciyes University's Faculty of Medicine, lasting from February 2000 to September 2006. A total of 98 patients were diagnosed with GBM after tumor resections. Patients' demographic, neurological, radiological, surgical, and clinical features and adjunct therapies were analyzed retrospectively. Results: Of the 98 patients, 36 (36.7%) were female and 62 (65.4%) were male. There were 15 patients (15.3%) still alive. The median survival time (MST) of the gross total resection and subtotal resection groups was 12 and 8 months, respectively. The group with postoperative Karnofsky performance scores (KPS) of >= 70 included 56 patients; their survival rate was 19.6% and their MST was 14 months (confidence interval [CI] 95%, 10-18). The postoperative KPS of <70 group included 42 patients; their MST was 4 months (CI 95%, 3-6) and their survival rate was 9.5%. After the radiotherapy, of the 73 patients who underwent chemotherapy, the survival rate was 19.2% and the MST was 14 months (CI 95%, 10-18). The group without chemotherapy had a MST of 2 months (CI 95%, 1-3) and a survival rate of 4%. In a univariate analysis, the MST of age groups I (<45), II (45-59), and III (>= 60) were 15 months (CI 95%, 7-23), 10 months (CI 95%, 7-13), and 5 months (CI 95%, 3-7), respectively. The preoperative and postoperative median tumor volume detected was 79 (14-668) and 6 (0-64) mm3, respectively. Conclusion: Multivariate Cox regression analyses showed that prognostic factors are young age, postoperative KPS, chemotherapy, and postoperative tumor volume.
引用
收藏
页码:795 / 804
页数:10
相关论文
共 50 条
  • [31] Multifocal glioblastoma multiforme: Prognostic factors and patterns of progression
    Andrel, J.
    Showalter, T. N.
    Andrews, D. W.
    Curran, W. J.
    White, J. S.
    Daskalakis, C.
    Werner-Wasik, M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S247 - S247
  • [32] The Assessment of Clinical Outcomes and Prognostic Factors in Glioblastoma Patients
    Demircan, Niyazi Volkan
    Erpolat, Ozge Petek
    Guzel, Caglar
    Senturk, Ertugrul
    Bora, Huseyin
    Karahacioglu, Eray
    [J]. TURKISH NEUROSURGERY, 2023, 33 (05) : 870 - 886
  • [33] Efficacy of Clinical Prognostic Factors on Survival in Patients with Glioblastoma
    Tugcu, Bekir
    Postalci, Lutfi Sinasi
    Gunaldi, Omur
    Tanriverdi, Osman
    Akdemir, Hidayet
    [J]. TURKISH NEUROSURGERY, 2010, 20 (02) : 117 - 125
  • [34] Clinical and immunohistochemical prognostic factors in adult glioblastoma patients
    Umesh, S.
    Tandon, A.
    Santosh, V.
    Anandh, B.
    Sampath, S.
    Chandramouli, B. A.
    Kolluri, V. R. Sastry
    [J]. CLINICAL NEUROPATHOLOGY, 2009, 28 (05) : 362 - 372
  • [35] Prognostic relevance of clinical and therapeutical aspects in patients with glioblastoma multiforme. Analysis of 99 patients
    Mangiola, A
    Anile, C
    De Bonis, P
    Pettorini, B
    Sabatino, G
    Mannino, S
    Pedone, C
    Maira, G
    [J]. NEURO-ONCOLOGY, 2005, 7 (03) : 312 - 312
  • [36] ACCELERATED FRACTIONATION RADIOTHERAPY FOR HOSPITALIZED GLIOBLASTOMA-MULTIFORME PATIENTS WITH POOR PROGNOSTIC FACTORS
    HERNANDEZ, JC
    MARUYAMA, Y
    YAES, R
    CHIN, HW
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1990, 9 (01) : 41 - 45
  • [37] Hypofractionated radiation therapy in patients with glioblastoma multiforme: Results of treatment and impact of prognostic factors
    Slotman, BJ
    Kralendonk, JH
    vanAlphen, HAM
    Kamphorst, W
    Karim, ABMF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (04): : 895 - 898
  • [38] BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
    Thomas Reithmeier
    Erika Graf
    Tobias Piroth
    Michael Trippel
    Marcus O Pinsker
    Guido Nikkhah
    [J]. BMC Cancer, 10
  • [39] Role of prognostic factors in glioblastoma multiforme: analysis of a monoinstitutional experience
    Lupattelli, M
    Anselmo, P
    Tarducci, R
    Nardi, M
    Chiarini, P
    Giovenali, P
    Latini, P
    [J]. RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S394 - S395
  • [40] HISTOLOGIC FACTORS OF PROGNOSTIC-SIGNIFICANCE IN THE GLIOBLASTOMA-MULTIFORME
    BURGER, PC
    VOLLMER, RT
    [J]. CANCER, 1980, 46 (05) : 1179 - 1186